Home > Back to Publisher > Report Information

The China Pharmaceutical Market: A Strategic Opportunity Analysis

Innovaro Pharmalicensing
January 1, 2007
100 Pages - SKU: PL1542270

Abstract Table of Contents Search inside this report Related Reports

Countries covered: China

The report discusses the whole of the Chinese pharmaceutical market, taking readers through the history and current state of the healthcare system through to the regulations governing the country and its growing R&D capabilities. China has become an attractive destination for R&D as new opportunities have emerged following its WTO (World Trade Organization) accession. Development has accelerated both industrially and scientifically, and today the Chinese pharmaceutical market is worth around $US12 billion.

1. Introduction
2. The Chinese healthcare system: 2.1. A historical perspective; 2.2. China’s healthcare system: Reforms
3. The Chinese pharmaceutical industry: 3.1. History; 3.2. Industry growth; 3.3. Pharmaceutical trade (exports and imports); 3.4. The pharmaceutical distribution structure in China; 3.5. Traditional Chinese medicine
4. Driving forces behind the Chinese pharmaceutical market: 4.1. Issues and opportunities in the pharmaceutical market; 4.2. Effect of the Chinese macro-environment on the pharmaceutical industry: A PEST analysis
5. Health insurance in China: 5.1. Government insurance; 5.2. Commercial medical insurance in China; 5.3. Health insurance take-up in China
6. Regulatory environment: 6.1. Chinese pharmaceutical regulations: A historical perspective; 6.2. Brief developmental history; 6.3. Drug regulatory structure and functions; 6.4. State Food and Drug Administration; 6.5. Responsibilities of the SFDA; 6.6. The registration process—medical devices; 6.7. The registration process—pharmaceuticals; 6.8. A few practical points regarding the management of SFDA registration
7. Legal reform: IPR: 7.1. Patent protection
8. Research and development in China: 8.1. Domestic R&D; 8.2. Collaborations with China; 8.3. Non-Chinese companies performing R&D in China
9. Clinical investigation in China: 9.1. Key drivers for rapid increase in number of global trials being conducted in China
10. Chinese vaccine market
11. Conclusion
12. China: Emerging biopharma opportunities: 12.1. Collaborative opportunities in life science R&D in China
13. Appendices: 13.1. References; 13.2. Resources; 13.3. Abbreviations; 13.4. Glossary; 13.5. Author biographies

More China Biopharmaceuticals Reports

Research Report on Chinese Bio-pharmaceutical Industry, 2012 by China Research and Intelligence Co., Ltd.
In China, biological products consist of vaccines, blood products, cytokine, diagnostic reagents and other active agents (including toxins, antigens, allergen, and recombinant DNA products, etc.). ...

Biosimilars: China Update by Datamonitor
Biosimilars: China Update provides analysis on the Chinese biogenerics market. It includes an overview of drivers and resistors to biogeneric uptake, market access strategies, key ...

Biosimilars: China Update by Datamonitor
Currently, there is no definition, guidance or pathway for biosimilars in China, with domestically manufactured versions of biologics, known as biogenerics. Due to limited R&D ...

Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products China Pharmaceutical Guidebook Series (4) (4th edition) by Access China Management Consulting Ltd.
The biopharmaceutical industry is one of the burgeoning industries. In the field of biopharmaceuticals, vast knowledge awaits people to explore. The biopharmaceuticals are diversified and ...

Research Report on China's Biopharmaceutical Industry, 2010-2012 by China Research and Intelligence Co., Ltd.
In China, biological products for human use include bacterial vaccines (including toxoid), viral vaccines, antitoxin and immune serum, blood products, cytokines, in vivo and in ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...

See all reports like this >>

The China Pharmaceutical Market: A Strategic Opportunity Analysis

Share this report

Other tasks

Research Assistance

Related Markets

Biopharmaceuticals Reports

Free Alert Me service